02 November 2023
via Zoom
NICE has received an appeal against the Final Draft Guidance on the above technology from the following organisations:
- GSK
- Myeloma UK
The appeal hearing originally scheduled for 2 November has been cancelled as the Final Draft Guidance has been withdrawn and the appraisal has been paused.
Please check the topic guidance page for further information and next steps.